Novel chemotherapy options for advanced thyroid tumors: Small molecules offer great hope

Current Opinion in Oncology

Volumn 20, Issue 1, 2008, Pages 19-24

  Deshpande, Hari A ^a   Gettinger, Scott N ^a   Sosa, Julie Ann ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis inhibitors; Novel treatments; Thyroid cancer; Tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CISPLATIN; COMBRESTATIN A4 PHOSPHATE; DOXORUBICIN; GEFITINIB; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; RETINOIC ACID; SORAFENIB; UNCLASSIFIED DRUG; VANDETANIB;

ANAPLASTIC CARCINOMA; ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG ERUPTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; METASTASIS; PRIORITY JOURNAL; REVIEW; THYROID CANCER; THYROID TUMOR;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CLINICAL TRIALS AS TOPIC; HUMANS; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36549015772     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f28373     Document Type: Review

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57:43-66. An authoritative source of cancer statistics in the United States including incidence and male to female ratios.
2. Colonna M, Guizard AV, Schvartz C, et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: A study of data from six cancer registries in France (1983-2000). Eur J Can 2007; 43:891-900. This is a good review of the changes that have been seen in the incidence of thyroid cancers over the past two decades.
3. Carling T, Udelsman R. Cancer of the endocrine system: Section 2 thyroid tumors. In: De Vita V, Hellman S, Rosenberg S, editors. Cancer principles and practice. Philadelphia: Lippincott Williams and Wilkins; 2005. pp. 1503-1521.
4. Kebebew E, Peng M, Reiff E, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006; 140:960-966. This is one of two references evaluating a differentiating agent to improve response to radioiodine.
5. Ekman ET, Lundell G, Tennvall J, et al. Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin North Am 1990; 23:523.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
7. Sivakumar B, Harry L, Paleolog E. Modulating angiogenesis more vs less. JAMA 2004; 292:972-977.
8. Cohen EE, Vokes EE, Rosen LS, et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers [abstract]. J Clin Oncol 2007; 25 (18S):6008.
9. Gupta V, Puttaswamy K, Lassoued W, et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma [abstract]. J Clin Oncol 2007; 25(18S):6019.
10. Sherman SI, Schlumberger MJ, Droz J, et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC) [abstract]. J Clin Oncol 2007; 25 (18S):6017.
11. Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91:2201-2204.
12. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer [abstract]. J Clin Oncol 2007; 25(18S):6020.
13. Zhang Y, Jia S, Liu Y, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 2007; 28:251-255. This is the second paper on using differentiating agents this time using a well known compound in leukemia treatment.
14. Messina M, Robinson B. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2007; 3:290-301. This paper makes fascinating reading but represents a treatment option that is still many years away from clinical use.
15. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62:7284-7290.
16. Fury MG, Solit DB, Su YB, et al. A phase I trial of intermittent high-dose gefitinib and docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2007; 59:467-475. Gefitinib is no longer approved for use in the United States but its activity in this study and that by Pennell et al. [12] is very encouraging and it may make a comeback in the treatment of thyroid cancer.
17. Brauckoff M, Lorenz K, Ukkat J, et al. Medullary thyroid carinoma. Scand J Surg 2004; 93:249-260.
18. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical and pathological predictors of survival in 1252 cases. Cancer 2006; 107:2134-2142. This population study was the largest of its kind and gave a fascinating look at stage and demographics of medullary thyroid cancer.
19. Rougier P, Calmettes C, La Planche A, et al. The values of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial thyroid carcinoma. Cancer 1983; 51:855-862.
20. Saad MF, Fritsche HA Jr, Samaan NA. Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrin Metab 1984; 58:889-894.
21. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA 1996; 276:1575-1579.
22. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999; 17:380-393.
23. Wedge S, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655.
24. Herbst R, Heymach J, O'Reilly M, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007; 16:239-249. This is a good basic science review of the mechanism of action of vandetanib.
25. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial [abstract]. J Clin Oncol 2007; 25 (18S):6018.
26. Chan P, Yau T, Epstein R, et al. Treatment outcomes in anaplastic thyroid carcinoma from 1966-2006: Failure of overall survival enhancement despite four decades of progress in surgery, radiotherapy and chemoradiation [abstract]. J Clin Oncol 2007; 25 (18S):16537.
27. Cornett WR, Sharma AK, Day TA, et al. Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 2007; 2:152-158. This and abstracts 26 and 28 offer an excellent review of one of the deadliest cancers known in man and the relative lack of progress against it.
28. Brignardello E, Gallo M, Balde I, et al. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. E J Endo 2007; 156:425-430. Another very good review of anaplastic thyroid cancer but with a shorter period of study than reference 26.
29. Cooney MM, Savvides P, Agarwala SS, et al. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma [abstract]. J Clin Oncol 2006; 24 (18S):5580.